Drug Trial Radar · NCT02219932
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Mar 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
646
Actual
Start
Sep 2014
Primary completion
Feb 2016
Study completion Feb 2016
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Aug 19, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to determine whether prolonged-release fampridine (10 mg twice daily) has a clinically meaningful effect on participant-reported walking ability over a 24-week study period. The secondary objectives are: to determine whether prolonged-release fampridine 10 mg taken twice daily (BID) has a clinically meaningful effect on dynamic and static balance, physical impact of multiple sclerosis (MS), and upper extremity function over a 24-week study period; to evaluate criteria for early assessment of response to fampridine that can predict clinically meaningful benefits in walking ability and balance; to assess the safety and tolerability of prolonged-release fampridine 10 mg twice daily over a 24-week treatment period.
Conditions
- Multiple Sclerosis
Interventions
fampridineDrug
PlaceboDrug
Matched placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants Achieving a Mean Improvement of ≥ 8 Points From Baseline on the Multiple Sclerosis Walking Scale (MSWS-12) Over 24 WeeksTime frame: Baseline to 24 weeks
Locations
87 sites in 11 countries. Site status is shown where the registry gives one.
Research site
Cullman, Alabama
Research site
Phoenix, Arizona
Research site
San Diego, California
Research site
Bradenton, Florida
Research Site
Orlando, Florida
Research site
Tampa, Florida
Research site
Tampa, Florida
Research site
West Palm Beach, Florida
Research site
Lexington, Kentucky
Research site
New Bedford, Massachusetts
Research site
Detroit, Michigan
Research site
Chesterfield, Missouri
Research site
Rochester, New York
Research site
Charlotte, North Carolina
Research site
Charlotte, North Carolina
Research site
Columbus, Ohio
Research site
Roanoke, Virginia
Research site
Pleven, Bulgaria
Research site
Plovdiv, Bulgaria
Research site
Sofia, Bulgaria
Research site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research site
Sofia, Bulgaria
Research site
Sofia, Bulgaria
Research Site
Sofia, Bulgaria
Research site
Brno, Czechia
Research site
Brno, Czechia
Research site
Choceň, Czechia
Research site
Havířov, Czechia
Research site
Jihlava, Czechia
Research site
Pardubice, Czechia
Research site
Prague, Czechia
Research site
Prague, Czechia
Research site
Teplice, Czechia
Research site
Helsinki, Finland
Research site
Oulu, Finland
Research site
Tampere, Finland
Research site
Turku, Finland
Research Site
Gallarate, Italy
Research site
Messina, Italy
Showing 40 of 87 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.